Cargando…

Ivacaftor Therapy in CF Patients: Single Center Experience

Ivacaftor is the first novel cystic fibrosis pharmaceutical that acts at the molecular level to potentiate cystic fibrosis transmembrane conductance regulator (CFTR) function and was first approved for clinical use in 2012. We are sharing our single center experience of five patients: four from pedi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mondal, Pritish, Loyson, Amber, Lascano, Jorge, Hegde, Satyanarayan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4590953/ https://www.ncbi.nlm.nih.gov/pubmed/26556432 http://dx.doi.org/10.1155/2014/947923

Ejemplares similares

Sweat rate analysis of ivacaftor potentiation of CFTR in non-CF adults
por: Kim, Jeeyeon, et al.
Publicado: (2018)

Flexible Bronchoscopy Under Bronchoscopist-Administered Moderate Sedation Versus General Anesthesia: A Comparative Study in Children
por: Mondal, Pritish, et al.
Publicado: (2018)

A Case Report of Pulmonary Exacerbation after Initiation of Lumacaftor/Ivacaftor Therapy in a CF Female with Complicated Lung Disease
por: Hatziagorou, Elpis, et al.
Publicado: (2018)

Individual and Group Response of Treatment with Ivacaftor on Airway and Gut Microbiota in People with CF and a S1251N Mutation
por: Kristensen, Maartje I., et al.
Publicado: (2021)

Optimizing Nasal Potential Difference Analysis for CFTR Modulator Development: Assessment of Ivacaftor in CF Subjects with the G551D-CFTR Mutation
por: Rowe, Steven M., et al.
Publicado: (2013)

Elexacaftor-Tezacaftor-Ivacaftor Treatment Reduces Abdominal Symptoms in Cystic Fibrosis-Early results Obtained With the CF-Specific CFAbd-Score
por: Mainz, Jochen G., et al.
Publicado: (2022)

Single-center In-hospital Cardiac Arrest Outcomes
por: Riley, Leonard E, et al.
Publicado: (2020)

Corrigendum: Elexacaftor-Tezacaftor-Ivacaftor treatment reduces abdominal symptoms in cystic fibrosis-early results obtained with the CF-specific CFAbd-Score
por: Mainz, Jochen G., et al.
Publicado: (2023)

Ivacaftor, not ivacaftor/lumacaftor, associated with lower pulmonary inflammation in preschool cystic fibrosis
por: Shanthikumar, Shivanthan, et al.
Publicado: (2022)

Elexacaftor/tezacaftor/ivacaftor-real-world clinical effectiveness and safety. A single-center Portuguese study
por: Lopes, Kelly, et al.
Publicado: (2023)

ROCK STUDY in CF: sustained anti-inflammatory effects of lumacaftor–ivacaftor in sputum and peripheral blood samples of adult patients with cystic fibrosis—an observational study
por: Arooj, Parniya, et al.
Publicado: (2023)

2229. Impact of Elexacaftor/tezacaftor/ivacaftor on Utilization of Antibiotics at a Single Pediatric Cystic Fibrosis Center
por: Elson, Elizabeth C, et al.
Publicado: (2023)

Long-Term Ivacaftor in People Aged 6 Years and Older with Cystic Fibrosis with Ivacaftor-Responsive Mutations
por: Pilewski, Joseph M., et al.
Publicado: (2020)

Insights Into Patient Variability During Ivacaftor-Lumacaftor Therapy in Cystic Fibrosis
por: Hanafin, Patrick O., et al.
Publicado: (2021)

Gene therapy for CF.
por: Eubanks, M
Publicado: (2001)

Tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2019)

Lumacaftor/ivacaftor for cystic fibrosis
Publicado: (2019)

Quantitative Method for the Analysis of Ivacaftor, Hydroxymethyl Ivacaftor, Ivacaftor Carboxylate, Lumacaftor, and Tezacaftor in Plasma and Sputum Using Liquid Chromatography With Tandem Mass Spectrometry and Its Clinical Applicability
por: Vonk, Steffie E. M., et al.
Publicado: (2021)

Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events
por: Schwarz, Carsten, et al.
Publicado: (2021)

Combination Therapy with Lumacaftor–Ivacaftor in Cystic Fibrosis. Keeping It Real
por: Sala, Marc A., et al.
Publicado: (2020)

Lumacaftor/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients
por: Kutney, Katherine, et al.
Publicado: (2019)

Effects of elexacaftor/tezacaftor/ivacaftor therapy on mental health of patients with cystic fibrosis
por: Piehler, Linus, et al.
Publicado: (2023)

Impact of Elexacaftor/Tezacaftor/Ivacaftor Therapy on the Cystic Fibrosis Airway Microbial Metagenome
por: Pallenberg, Sophia T., et al.
Publicado: (2022)

Tezacaftor/Ivacaftor therapy has negligible effects on the cystic fibrosis gut microbiome
por: Marsh, Ryan, et al.
Publicado: (2023)

Bridging for lung transplantation with lumacaftor/ivacaftor
por: Pedersen, Søren Sperling, et al.
Publicado: (2018)

Elexacaftor/tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2021)

Computed Tomographic Changes in Patients with Cystic Fibrosis Treated by Combination Therapy with Lumacaftor and Ivacaftor
por: Arnaud, François, et al.
Publicado: (2021)

Pancreatitis in A Patient with Cystic Fibrosis Taking Ivacaftor
por: Petrocheilou, Argyri, et al.
Publicado: (2020)

Lumacaftor-ivacaftor in the treatment of cystic fibrosis: design, development and place in therapy
por: Connett, GJ
Publicado: (2019)

Changing profiles of patients undergoing transurethral resection of the prostate over a decade: A single-center experience
por: Agrawal, Manav, et al.
Publicado: (2019)

Elexacaftor–Tezacaftor–Ivacaftor Therapy for Cystic Fibrosis Patients with The F508del/Unknown Genotype
por: Comegna, Marika, et al.
Publicado: (2021)

Real-World Outcomes Among Patients with Cystic Fibrosis Treated with Ivacaftor: 2012–2016 Experience
por: Higgins, Mark, et al.
Publicado: (2020)

Impact of elexacaftor/tezacaftor/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF Registry
por: Sutharsan, Sivagurunathan, et al.
Publicado: (2023)

Cytochrome P450 3A4 Induction: Lumacaftor versus Ivacaftor Potentially Resulting in Significantly Reduced Plasma Concentration of Ivacaftor
por: Schneider, Elena K.
Publicado: (2018)

The impact of ivacaftor on sinonasal pathology in S1251N-mediated cystic fibrosis patients
por: Gostelie, Romee, et al.
Publicado: (2020)

Effect of Ivacaftor on Objective and Subjective Measures of Cough in Patients with Cystic Fibrosis
por: Faruqi, Shoaib, et al.
Publicado: (2016)

Pharmacokinetic and Drug–Drug Interaction Profiles of the Combination of Tezacaftor/Ivacaftor
por: Garg, Varun, et al.
Publicado: (2019)

Impact of pharmacy services on time to elexacaftor-tezacaftor-ivacaftor initiation
por: Roder, Lauren, et al.
Publicado: (2022)

Lumacaftor/ivacaftor changes the lung microbiome and metabolome in cystic fibrosis patients
por: Neerincx, Anne H., et al.
Publicado: (2021)

Impact of elexacaftor/tezacaftor/ivacaftor on depression and anxiety in cystic fibrosis
por: Zhang, Lijia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_thp2pol86lq0oijqlf65rna853